Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ultan McDermott

Showing results (21-30 of 114) with videos related to

Pageof 12
Sort By:
Molecular Cancer Therapeutics|April 17, 2008
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitorNadia Godin-Heymann, Lindsey Ulkus, Brian W Brannigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolitesDaniel Broderick Longley, Wendy Louise Allen, Ultan McDermott, et al.
Cancer Research Communications|March 27, 2023
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant CellsMatthew J Martin, Nicolas Floc'h, Matthias Pfeifer, et al.
BMC Genomics|February 26, 2025
A benchmark comparison of CRISPRn guide-RNA design algorithms and generation of small single and dual-targeting libraries to boost screening efficiencySebastian Lukasiak, Alex Kalinka, Nikhil Gupta, et al.
Patterns (New York, N.Y.)|November 18, 2020
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR ScreensIñigo Ayestaran, Ana Galhoz, Elmar Spiegel, et al.
Communications Biology|May 22, 2021
Genome-wide CRISPR/Cas9 deletion screen defines mitochondrial gene essentiality and identifies routes for tumour cell viability in hypoxiaLuke W Thomas, Cinzia Esposito, Rachel E Morgan, et al.
Nature Communications|August 25, 2018
The germline genetic component of drug sensitivity in cancer cell linesMichael P Menden, Francesco Paolo Casale, Johannes Stephan, et al.
Cancer Discovery|January 1, 2013
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinomaLei He, Kristine Torres-Lockhart, Nicole Forster, et al.
Nature Reviews. Drug Discovery|November 25, 2017
Steps forward for cancer precision medicineRoberto Salgado, Helen Moore, John W M Martens, et al.
Cancer Research|August 9, 2003
Identification of 5-fluorouracil-inducible target genes using cDNA microarray profilingPamela J Maxwell, Daniel B Longley, Tariq Latif, et al.
Pageof 12

Showing results (21-30 of 114) with videos related to

Sort By:
Pageof 12
Molecular Cancer Therapeutics|April 17, 2008
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitorNadia Godin-Heymann, Lindsey Ulkus, Brian W Brannigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolitesDaniel Broderick Longley, Wendy Louise Allen, Ultan McDermott, et al.
Cancer Research Communications|March 27, 2023
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant CellsMatthew J Martin, Nicolas Floc'h, Matthias Pfeifer, et al.
BMC Genomics|February 26, 2025
A benchmark comparison of CRISPRn guide-RNA design algorithms and generation of small single and dual-targeting libraries to boost screening efficiencySebastian Lukasiak, Alex Kalinka, Nikhil Gupta, et al.
Patterns (New York, N.Y.)|November 18, 2020
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR ScreensIñigo Ayestaran, Ana Galhoz, Elmar Spiegel, et al.
Communications Biology|May 22, 2021
Genome-wide CRISPR/Cas9 deletion screen defines mitochondrial gene essentiality and identifies routes for tumour cell viability in hypoxiaLuke W Thomas, Cinzia Esposito, Rachel E Morgan, et al.
Nature Communications|August 25, 2018
The germline genetic component of drug sensitivity in cancer cell linesMichael P Menden, Francesco Paolo Casale, Johannes Stephan, et al.
Cancer Discovery|January 1, 2013
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinomaLei He, Kristine Torres-Lockhart, Nicole Forster, et al.
Nature Reviews. Drug Discovery|November 25, 2017
Steps forward for cancer precision medicineRoberto Salgado, Helen Moore, John W M Martens, et al.
Cancer Research|August 9, 2003
Identification of 5-fluorouracil-inducible target genes using cDNA microarray profilingPamela J Maxwell, Daniel B Longley, Tariq Latif, et al.
Pageof 12